resmetirom

5 FDA Decisions to Watch in Q1
BioSpace
Tue, 01/2/24 - 11:24 am
FDA
Iovance Biotherapeutics
melanoma
lifileucel
Minerva Neurosciences
schizophrenia
roluperidone
Viatris
Mapi Pharma
MS
multiple sclerosis
GA Depot
Madrigal Pharmaceuticals
NASH
resmetirom
Vertex Pharmaceuticals
CRISPR Therapeutics
exa-cel
beta thalassemia
Madrigal Pursues $500M Public Offering with NASH Market Up for Grabs
BioSpace
Fri, 09/29/23 - 11:58 am
Madrigal Pharmaceuticals
NASH
resmetirom
The 10 highest value R&D projects in biopharma
Fierce Biotech
Wed, 09/6/23 - 10:17 am
R&D
biotech
Merck
sotatercept
Daiichi Sankyo
AstraZeneca
Dato-DXd
Novo Nordisk
CagriSema
Eli Lilly
donanemab
Karuna Therapeutics
Zai Lab
KarXT
Moderna Therapeutics
mRNA-1647
Novartis
iptacopan
Madrigal Pharmaceuticals
resmetirom
Cytokinetics
aficamten
Roche
Chugai
tiragolumab
Madrigal shares triple on positive NASH study results
BioPharma Dive
Mon, 12/19/22 - 12:22 pm
Madrigal Pharmaceuticals
clinical trials
NASH
resmetirom
A NASH player touts positive PhIII data, but true test still lies ahead
Endpoints
Mon, 01/31/22 - 11:04 am
NASH
clinical trials
Madrigal Pharmaceuticals
resmetirom
NAFLD
3 Biotech Stocks With Major Catalysts in January
Motley Fool
Tue, 01/4/22 - 10:25 am
Novavax
vaccines
COVID-19
FDA
Intercept Pharma
Ocaliva
NASH
Madrigal Pharmaceuticals
resmetirom